Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities

(2015) H. Green et al.   CLINICAL CANCER RESEARCH

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study

(2015) Manuela Quaresma et al.   LANCET

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

(2015) L. Christiansson et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic cancer: The microenvironment needs attention too!

(2015) M.V. Apte et al.   PANCREATOLOGY

Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients

(2015) Bao-Hong Fu et al.   TUMOR BIOLOGY

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis

(2014) Ming-Yi Xu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients

(2014) Yazan S. Khaled et al.   Journal of Immunology Research

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer

(2013) Nicola E. Annels et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

(2013) Y. Homma et al.   Clinical & Translational Oncology

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer

(2013) Kolaparthi Venkatasubbarao et al.   Molecular Cancer

New insights into pancreatic cancer biology

(2012) M. Hidalgo   ANNALS OF ONCOLOGY

Immunosuppressive activity of CD14+ HLA-DR− cells in squamous cell carcinoma of the head and neck

(2012) Kazuaki Chikamatsu et al.   CANCER SCIENCE

On the armament and appearances of human myeloid-derived suppressor cells

(2012) Isabel Poschke et al.   CLINICAL IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer

(2012) Su-Ni Tang et al.   PLoS One

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

(2011) Rachel F. Gabitass et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

(2010) Lorna Rettig et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy

(2008) S. A. Veltkamp et al.   ONCOLOGIST